Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930721 | 0.91 | UBE2M (0.39) | MAPTOPRM1GRIN1GRIN2B | |
| SCHEMBL13952184 | 0.85 | OPRM1 (0.45) | MAPTOPRM1GRIN1GRIN2B | |
| SCHEMBL13930670 | 0.84 | OPRM1 (0.47) | ALDH1A1OPRM1GRIN1GRIN2B | |
| SCHEMBL13952138 | 0.83 | OPRM1 (0.41) | OPRM1GRIN1GRIN2B | |
| SCHEMBL13930692 | 0.82 | UBE2M (0.49) | MAPTALDH1A1OPRM1KMT2AHPGD | |
| SCHEMBL13930729 | 0.82 | RORC (0.56) | OPRM1GRIN1GRIN2B | |
| SCHEMBL13930718 | 0.81 | TPSAB1 (0.51) | OPRM1GRIN1GRIN2B | |
| SCHEMBL13930722 | 0.80 | OPRM1 (0.41) | ALDH1A1KDM4EOPRM1GRIN1GRIN2B | |
| SCHEMBL13930723 | 0.80 | UBE2M (0.43) | MAPTOPRM1 | |
| SCHEMBL13930730 | 0.79 | UBE2M (0.51) | OPRM1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | MAPT 2479/4885ALDH1A1 1/4885KDM4E 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.